INTEGRATED LABORATORY ABNORMALITY PROFILES OF UPADACITINIB WITH UP TO 4.5 YEARS OF EXPOSURE IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED IN THE SELECT PHASE 3 PROGRAM

被引：0
|
作者：
Charles-Schoeman, C. [1 ]
Giles, J. T. [2 ]
Lane, N. [3 ]
Choy, E. [4 ]
Furst, D. [5 ]
Vencovsky, J. [6 ]
Wilson, A. G. [7 ]
Burmester, G. R. [8 ]
Shaw, T. [9 ]
Song, Y. [9 ]
Camp, H. [9 ]
Khan, N. [9 ]
Yee, J. [9 ]
Anyanwu, S. [9 ]
Mcinnes, I. [10 ]
机构：
[1] Univ Calif Los Angeles, Rheumatol, Los Angeles, CA USA
[2] Columbia Univ, Rheumatol, New York, NY USA
[3] Univ Calif Davis, Rheumatol, Sacramento, CA USA
[4] Cardiff Univ, CREATE Ctr, Rheumatol, Cardiff, Wales
[5] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
[6] Inst Rheumatol, Rheumatol, Prague, Czech Republic
[7] Univ Coll Dublin, Conway Inst, Ctr Arthrit Res, Dublin, Ireland
[8] Charite, Rheumatol, Berlin, Germany
[9] AbbVie Inc, Immunol, N Chicago, IL USA
[10] Univ Glasgow, Inst Infect Immun & Inflammat, Glasgow, Lanark, Scotland
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2021年 / 80卷
关键词：
D O I：
10.1136/annrheumdis-2021-eular.1815
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
OP0128
引用
收藏
页码：72 / 73
页数：2
相关论文
共 50 条
  • [31] Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme
    Fleischmann, Roy
    Curtis, Jeffrey R.
    Charles-Schoeman, Christina
    Mysler, Eduardo
    Yamaoka, Kunihiro
    Richez, Christophe
    Palac, Hannah
    Dilley, Deanne
    Liu, Jianzhong
    Strengholt, Sander
    Burmester, Gerd
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 (09) : 1130 - 1141
  • [32] Integrated Exposure-Response Analyses for Upadacitinib Efficacy and Effects on Laboratory Parameters in Rheumatoid Arthritis - Analyses of Phase 2b Studies
    Mohamed, Mohamed-Eslam
    Winzenborg, Insa
    Doelger, Eva
    Noertersheuser, Peter
    Camp, Heidi S.
    Meerwein, Sebastian
    Othman, Ahmed A.
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [33] TREATING RHEUMATOID ARTHRITIS PATIENTS WITH MODERATE DISEASE ACTIVITY: AN ANALYSIS OF THE UPADACITINIB SELECT PHASE III RANDOMISED STUDIES
    Conaghan, Phillip G.
    Pavelka, Karel
    Hsieh, Song-Chou
    Bonnington, Terri-Leigh
    Kent, Toby C.
    Edwards, Christopher J.
    RHEUMATOLOGY, 2021, 60
  • [34] INCIDENCE AND RISK OF VENOUS THROMBOEMBOLIC EVENTS AMONG PATIENTS WITH RHEUMATOID ARTHRITIS ENROLLED IN THE UPADACITINIB SELECT CLINICAL TRIAL PROGRAM
    Choy, E.
    Mcinnes, I.
    Cush, J.
    Aelion, J.
    Rigby, W.
    Song, Y.
    Meerwein, S.
    Liu, J.
    Khan, N.
    Suboticki, J.
    Cohen, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 313 - 314
  • [35] LONG-TERM SAFETY AND EFFICACY OF UPADACITINIB OR ADALIMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS AT 3 YEARS FROM THE SELECT-COMPARE STUDY
    Fleischmann, R.
    Mysler, E.
    Bessette, L.
    Peterfy, C.
    Durez, P.
    Tanaka, Y.
    Swierkot, J.
    Khan, N.
    Bu, X.
    Li, Y.
    Song, I. H.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 251 - 252
  • [36] Long-Term Safety and Efficacy of Upadacitinib or Adalimumab in Patients with Rheumatoid Arthritis: Results at 3 Years from the SELECT-COMPARE Study
    Fleischmann, Roy
    Mysler, Eduardo
    Bessette, Louis
    Peterfy, Charles
    Durez, Patrick
    Tanaka, Yoshiya
    Swierkot, Jerzy
    Khan, Nasser
    Bu, Xianwei
    Li, Yihan
    Song, In-Ho
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 1708 - 1710
  • [37] Safety Profile of Subcutaneous Abatacept Focusing on Clinically Relevant Events in Patients with Rheumatoid Arthritis (RA) and up to 4.5 Years of Exposure.
    Alten, Rieke
    Kaine, Jeffrey L.
    Keystone, Edward
    Nash, Peter T.
    Delaet, Ingrid
    Qi, Keqin
    Genovese, Mark C.
    ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S150 - S151
  • [38] Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study
    Fleischmann, Roy
    Mysler, Eduardo
    Bessette, Louis
    Peterfy, Charles G.
    Durez, Patrick
    Tanaka, Yoshiya
    Swierkot, Jerzy
    Khan, Nasser
    Bu, Xianwei
    Li, Yihan
    Song, In-Ho
    RMD OPEN, 2022, 8 (01):
  • [39] TREATMENT WITH UPADACITINIB RESULTS IN THE NORMALIZATION OF KEY PATHOBIOLOGIC PATHWAYS IN PATIENTS WITH RHEUMATOID ARTHRITIS: BIOMARKER RESULTS FROM THE PHASE 3 SELECT-NEXT AND SELECT-BEYOND STUDIES
    Sornasse, Thierry
    Sokolove, Jeremy
    McInnes, Iain
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 365 - 366
  • [40] PREDICTORS OF REMISSION IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH UPADACITINIB OR ADALIMUMAB IN THE SELECT-COMPARE PHASE 3 STUDY: CLINICAL STATUS AT WEEK 12, BUT NOT STANDARD LABORATORY MEASURES, PROVIDES THE BEST CURRENT PREDICTOR OF REMISSION AT WEEK 26
    Sornasse, T.
    Cai, F.
    Hong, F.
    Anyanwu, S.
    Song, I. H.
    Bukhari, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 533 - 534
12345